These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19786638)

  • 1. Utility of cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease.
    Gange CA; Link MS; Maron MS
    Circulation; 2009 Sep; 120(13):e96-7. PubMed ID: 19786638
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe left ventricular hypertrophy in Anderson-Fabry disease.
    Bhatia GS; Leahy JF; Connolly DL; Davis RC
    Heart; 2004 Oct; 90(10):1136. PubMed ID: 15367506
    [No Abstract]   [Full Text] [Related]  

  • 3. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study.
    Takenaka T; Teraguchi H; Yoshida A; Taguchi S; Ninomiya K; Umekita Y; Yoshida H; Horinouchi M; Tabata K; Yonezawa S; Yoshimitsu M; Higuchi K; Nakao S; Anan R; Minagoe S; Tei C
    J Cardiol; 2008 Feb; 51(1):50-9. PubMed ID: 18522775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Urinary Mulberry Bodies Leads to Diagnosis of Fabry Cardiomyopathy: A Simple Clue in the Urine Sediment.
    Yano T; Takahashi R; Yamashita T; Nagano N; Ishikawa A; Sakurai A; Maruyama H; Miura T
    Circ Heart Fail; 2017 Dec; 10(12):. PubMed ID: 29203563
    [No Abstract]   [Full Text] [Related]  

  • 5. Images in cardiovascular medicine. Diagnostic utility of cardiac magnetic resonance imaging in monozygotic twins with hypertrophic cardiomyopathy and identical pattern of left ventricular hypertrophy.
    Maron BJ; Haas TS; Lesser JR
    Circulation; 2007 Jun; 115(24):e627-8. PubMed ID: 17576874
    [No Abstract]   [Full Text] [Related]  

  • 6. [End-stage cardiac manifestations and autopsy findings in patients with cardiac fabry disease].
    Teraguchi H; Takenaka T; Yoshida A; Taguchi S; Ninomiya K; Yoshida H; Horinouchi M; Yonezawa S; Nakao S; Minagoe S; Tei S
    J Cardiol; 2004 Feb; 43(2):98-9. PubMed ID: 15046052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease.
    Brakch N; Dormond O; Bekri S; Golshayan D; Correvon M; Mazzolai L; Steinmann B; Barbey F
    Eur Heart J; 2010 Jan; 31(1):67-76. PubMed ID: 19773225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Electrocardiogram in Fabry's disease].
    Jastrzebski M; Petkow-Dimitrow P
    Kardiol Pol; 2008 Jun; 66(6):688-92; discussion 692-3. PubMed ID: 18626840
    [No Abstract]   [Full Text] [Related]  

  • 9. An unusual cause of dyspnea.
    Jamali AH; Ahmed RM; Stein H
    Cardiol Rev; 2004; 12(1):10-4. PubMed ID: 14667257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Fabry's disease: an unusual cause of left ventricular hypertrophy.
    Nunes JP; Costa O; Faria Mdo S; Almeida PB; Lacerda L
    Nat Clin Pract Cardiovasc Med; 2007 Nov; 4(11):630-3. PubMed ID: 17957210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease.
    Hasegawa H; Takano H; Shindo S; Takeda S; Funabashi N; Nakagawa K; Toyozaki T; Kuwabara Y; Komuro I
    Circulation; 2006 Apr; 113(16):e720-1. PubMed ID: 16636179
    [No Abstract]   [Full Text] [Related]  

  • 12. Importance of oblique fiber orientation for left ventricular wall deformation.
    Shapiro EP; Rademakers FE
    Technol Health Care; 1997 Apr; 5(1-2):21-8. PubMed ID: 9134616
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of left ventricular hypertrophy by magnetic resonance imaging.
    Shapiro EP
    Am J Card Imaging; 1994 Oct; 8(4):310-5. PubMed ID: 7819725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fabry disease and ischemic cerebrovascular disease].
    Orimo S
    Nihon Rinsho; 1993 Dec; 51 Suppl():650-5. PubMed ID: 8121058
    [No Abstract]   [Full Text] [Related]  

  • 15. 'Atypical' clinical variants of Anderson-Fabry disease.
    Sessa A; Meroni M; Battini G; Amato M; Righetti M; Bertella M; Brambilla P; Bertagnolio B
    Nephron; 2001 Dec; 89(4):469-70. PubMed ID: 11721170
    [No Abstract]   [Full Text] [Related]  

  • 16. A non invasive approach to differentiate physiological versus pathological left ventricle hypertrophy.
    Bayes de Luna A
    J Med Liban; 1999; 47(3):190-3. PubMed ID: 10550945
    [No Abstract]   [Full Text] [Related]  

  • 17. [Left ventricular hypertrophy and end-stage renal failure of unknown etiology: Fabry disease?].
    Arévalo-Gómez A; Rivera-García S; López-Muñiz A; Barriales-Villa R
    Rev Clin Esp; 2012 May; 212(5):265-6. PubMed ID: 22112280
    [No Abstract]   [Full Text] [Related]  

  • 18. Wide complex beats with ventricular hypertrophy: what is the mechanism?
    Omar AR; Harris L; Cameron DA; Chauhan VS
    J Cardiovasc Electrophysiol; 2006 Oct; 17(10):1150-2. PubMed ID: 16989653
    [No Abstract]   [Full Text] [Related]  

  • 19. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis.
    Yousef Z; Elliott PM; Cecchi F; Escoubet B; Linhart A; Monserrat L; Namdar M; Weidemann F
    Eur Heart J; 2013 Mar; 34(11):802-8. PubMed ID: 22736678
    [No Abstract]   [Full Text] [Related]  

  • 20. A tale of two ventricles: unusual causes of left ventricular hypertrophy.
    Pearlamn AS
    Am Heart Hosp J; 2004; 2(4):235-8. PubMed ID: 15538061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.